Jadvar Hossein
Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA 90033 USAPresident, Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Tomography. 2015 Sep;1(1):18-22. doi: 10.18383/j.tom.2015.00130.
Prostate cancer is a prevalent public health problem worldwide. Over the past decade, there has been tremendous research activity in the potential use of positron emission tomography with a number of radiotracers targeted to various biological aspects of this complex tumor. Systematic reviews and meta-analysis are important contributions to the relevant literature that summarize the evidence while reducing the effect of various sources of bias in the published data. The accumulation of relevant data in this clinical setting has recently provided the opportunity for systematic reviews. In this brief article, I summarize the published systematic reviews and meta-analysis of positron emission tomography in prostate cancer. Most robust evidence suggests a probable role for first-line use of positron emission tomography with radiolabeled choline in restating patients with biochemical relapse of prostate cancer with the diagnostic performance that appears to be positively associated with the serum prostate specific antigen level and velocity. Future systematic reviews will be needed for other emerging radiotracers such as those based on prostate specific membrane antigen and gastrin-releasing peptide receptor.
前列腺癌是全球普遍存在的公共卫生问题。在过去十年中，针对正电子发射断层扫描（PET）在这种复杂肿瘤的各种生物学特性方面潜在应用的研究活动十分活跃，使用了多种放射性示踪剂。系统评价和荟萃分析对相关文献具有重要贡献，它们在总结证据的同时，减少了已发表数据中各种偏倚来源的影响。在这一临床背景下，相关数据的积累最近为系统评价提供了契机。在这篇简短的文章中，我总结了已发表的关于PET在前列腺癌中的系统评价和荟萃分析。最有力的证据表明，对于前列腺癌生化复发患者，一线使用放射性标记胆碱的PET可能具有重要作用，其诊断性能似乎与血清前列腺特异性抗原水平及变化率呈正相关。对于其他新兴的放射性示踪剂，如基于前列腺特异性膜抗原和胃泌素释放肽受体的示踪剂，未来还需要进行系统评价。
